Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE® mobile health study.
Sousa-Pinto B, Ramanauskaite A, Neisinger S, Witte-Händel E, Gimenez-Arnau AM, Guillet C, Parisi CAS, Katelaris CH, Fomina D, Larenas-Linnemann D, García E, Kocatürk E, Siebenhaar F, Lima H, Kaidashev I, Nasr I, Canales IO, Ojeda IC, Hébert J, Bousquet J, Bernstein JA, Peter J, Sanchez J, Sousa JIL, Kulthanan K, Weller K, Godse K, Rutkowski K, Lapina L, Bouillet L, Han LL, Ensina LF, Gonçalo M, Magerl M, van Doorn M, Metz M, Khoshkhui M, Hide M, Türk M, Kurjāne N, Conlon N, Salameh P, Kolkhir P, Asero R, Stepanenko R, Altrichter S, Gil-Mata S, Thomsen SF, Zuberbier T, Tsaryk V, Ye YM, Brzoza Z, Zhao Z, Maurer M. Sousa-Pinto B, et al. Among authors: van doorn m. Allergy. 2024 Oct 24. doi: 10.1111/all.16371. Online ahead of print. Allergy. 2024. PMID: 39445583
Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Mohammad Porras N, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Dikicier BS, van Doorn MBA, Thomsen SF, van den Reek JMPA, Röckmann H. Soegiharto R, et al. Among authors: van doorn mba. Allergy. 2024 Oct 8. doi: 10.1111/all.16334. Online ahead of print. Allergy. 2024. PMID: 39377745
KECORT Study: An International e-Delphi Study on the Treatment of KEloids Using Intralesional CORTicosteroids in Clinical Practice.
Yin Q, Wolkerstorfer A, Lapid O, Qayumi K, Alam M, Al-Niaimi F, Artzi O, van Doorn MBA, Goutos I, Haedersdal M, Hsu CK, Manuskiatti W, Monstrey S, Mustoe TA, Ogawa R, Ozog D, Park TH, Pötschke J, Rossi A, Tan ST, Téot L, Wood FM, Yu N, Gibbs S, Niessen FB, van Zuijlen PPM. Yin Q, et al. Among authors: van doorn mba. Am J Clin Dermatol. 2024 Nov;25(6):1009-1017. doi: 10.1007/s40257-024-00888-7. Epub 2024 Sep 19. Am J Clin Dermatol. 2024. PMID: 39298112 Free PMC article.
Needle-free jet injector treatment with bleomycin is efficacious in patients with severe keloids: a randomized, double-blind, placebo-controlled trial.
Bekkers VZ, Zdunczyk KM, Bik L, Ten Voorde W, Aarts P, Oerlemans F, Bohoslavsky R, Haedersdal M, Prens EP, Rissmann R, van Doorn MBA. Bekkers VZ, et al. Among authors: van doorn mba. Clin Exp Dermatol. 2024 Nov 22;49(12):1668-1675. doi: 10.1093/ced/llae254. Clin Exp Dermatol. 2024. PMID: 39030712 Clinical Trial.
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Porras NM, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Sevimli Dikicier B, van Doorn MBA, Thomsen SF, van den Reek JMPA, Röckmann H. Soegiharto R, et al. Among authors: van doorn mba. JAMA Dermatol. 2024 Sep 1;160(9):927-935. doi: 10.1001/jamadermatol.2024.2056. JAMA Dermatol. 2024. PMID: 39018068
Guselkumab treatment normalizes the stratum corneum ceramide profile and alleviates barrier dysfunction in psoriasis: results of a randomized controlled trial.
Rousel J, Mergen C, Bergmans ME, Bruijnincx LJ, de Kam ML, Klarenbeek NB, Niemeyer-van der Kolk T, van Doorn MBA, Bouwstra JA, Rissmann R; Next-Generation ImmunoDermatology Consortium (NGID). Rousel J, et al. Among authors: van doorn mba. J Lipid Res. 2024 Aug;65(8):100591. doi: 10.1016/j.jlr.2024.100591. Epub 2024 Jul 9. J Lipid Res. 2024. PMID: 38992724 Free PMC article. Clinical Trial.
176 results